Telix Pharmaceuticals Limited
ASXTelix Pharmaceuticals heads into its May 21 results with one of the most contested short books in Australian biotech — and a CEO who has been quietly buying into the weakness. Short sellers remain heavily positioned. Short interest runs near 15.3% of the free float, a high reading by any standard, and while it has eased modestly over the past week (down roughly 2.8%), it has…
Snapshot as of 20 May 2026
Telix Pharmaceuticals heads into its May 21 results with one of the most contested short books in Australian biotech — and a CEO who has been quietly buying into the weakness. Short sellers remain heavily positioned.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TLX — free to start on ORTEX.
Sign up for free →Open TLX on ORTEX